Treating patients for cardiovascular protection: combination therapy to achieve complete renin-angiotensin system blockade (Q36873154)

16 August 2017

1 reference

title

Treating patients for cardiovascular protection: combination therapy to achieve complete renin-angiotensin system blockade (English)

1 reference

16 August 2017

Alan H Gradman

1 reference

16 August 2017

publication date

1 January 2007

1 reference

16 August 2017

published in

Preventive Cardiology

1 reference

16 August 2017

1 reference

16 August 2017

1 reference

16 August 2017

page(s)

147-155

1 reference

Vascular inflammation and the renin-angiotensin system

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2007.07169.X

Tissue renin-angiotensin system in myocardial hypertrophy and failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2007.07169.X

Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2007.07169.X

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2007.07169.X

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2007.07169.X

A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2007.07169.X

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2007.07169.X

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2007.07169.X

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2007.07169.X

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2007.07169.X

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2007.07169.X

Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2007.07169.X

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2007.07169.X

Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2007.07169.X

RAS inhibition in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2007.07169.X

The prothrombotic paradox of hypertension: role of the renin-angiotensin and kallikrein-kinin systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2007.07169.X

Dual blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2007.07169.X

The AT2 receptor--a matter of love and hate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2007.07169.X

The role of the AT2 receptor in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2007.07169.X

Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2007.07169.X

A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2007.07169.X

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2007.07169.X

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2007.07169.X

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2007.07169.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2007.07169.X

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2007.07169.X

Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2007.07169.X

Angiotensin-converting-enzyme inhibition in stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2007.07169.X

Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2007.07169.X

The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2007.07169.X

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2007.07169.X

10.1111/J.1520-037X.2007.07169.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference